^
BIOMARKER:

EGFR exon 19 deletion

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR exon 19 deletion
NSCLC
tislelizumab
Sensitive: C3 – Early Trials
ESMO-IO 2021 - 6 days
EGFR exon 19 deletion
NSCLC
osimertinib
Sensitive: A1 - Approval
Sci Rep - 1 week
EGFR exon 19 deletion
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
gefitinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
dacomitinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
erlotinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
erlotinib + ramucirumab
Sensitive: A1 - Approval
EGFR exon 19 deletion
Lung Non-Squamous Non-Small Cell Cancer
osimertinib
Sensitive: A2 - Guideline
EGFR exon 19 deletion
LUAD
gefitinib
Sensitive: B - Late Trials
EGFR exon 19 deletion
NSCLC
icotinib
Sensitive: B - Late Trials
EGFR exon 19 deletion
NSCLC
gefitinib + rivoceranib
Sensitive: B - Late Trials
EGFR exon 19 deletion
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: B - Late Trials
EGFR exon 19 deletion
LUAD
afatinib
Sensitive: B - Late Trials
EGFR exon 19 deletion
NSCLC
gefitinib + ramucirumab
Sensitive: B - Late Trials
EGFR exon 19 deletion
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor
Sensitive: B - Late Trials
EGFR exon 19 deletion
NSCLC
aumolertinib
Sensitive: B - Late Trials
EGFR exon 19 deletion
LUAD
osimertinib
Resistant: C1 - Off-label
EGFR exon 19 deletion
Small Cell Lung Cancer
gefitinib
Sensitive: C1 - Off-label
EGFR exon 19 deletion
Lung Cancer
gefitinib
Sensitive: C1 - Off-label
EGFR exon 19 deletion
NSCLC
osimertinib + gefitinib
Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion
NSCLC
anlotinib + icotinib
Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion
NSCLC
amivantamab-vmjw
Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion
NSCLC
EGF816
Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion
NSCLC
amivantamab-vmjw + lazertinib
Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion
NSCLC
U3-1402
Sensitive: C2 – Inclusion Criteria
EGFR exon 19 deletion
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
erlotinib + anlotinib
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
EGFR inhibitor
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
rivoceranib + camrelizumab
Resistant: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
PD1 inhibitor
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
afatinib + DFP-14323
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
gefitinib + durvalumab
Resistant: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
bevacizumab + erlotinib
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
olaparib + gefitinib
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
X-396
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
brigatinib
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
alectinib
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
lorlatinib
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
gefitinib + fruquintinib
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
anlotinib + APL-502
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
gefitinib + anlotinib
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
NSCLC
bevacizumab + osimertinib
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
LUAD
brigatinib
Sensitive: C3 – Early Trials
EGFR exon 19 deletion
Thymic Carcinoma
icotinib
Sensitive: C4 – Case Studies
EGFR exon 19 deletion
NSCLC
bevacizumab + atezolizumab
Sensitive: C4 – Case Studies
EGFR exon 19 deletion
NSCLC
erlotinib + ado-trastuzumab emtansine
Sensitive: D – Preclinical
EGFR exon 19 deletion
NSCLC
lenalidomide
Sensitive: D – Preclinical
EGFR exon 19 deletion
NSCLC
CH7233163
Sensitive: D – Preclinical
EGFR exon 19 deletion
Lung Cancer
BMS-722782
Sensitive: D – Preclinical